Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2004 | 1 |
2006 | 1 |
2014 | 1 |
2016 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
Clin Breast Cancer. 2023 Dec;23(8):813-824. doi: 10.1016/j.clbc.2023.06.009. Epub 2023 Jun 20.
Clin Breast Cancer. 2023.
PMID: 37419745
Review.
Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.
Hicks D, O'Regan RM.
Hicks D, et al. Among authors: o regan rm.
J Clin Oncol. 2022 Apr 10;40(11):1142-1146. doi: 10.1200/JCO.21.02850. Epub 2022 Feb 24.
J Clin Oncol. 2022.
PMID: 35201844
Review.
Item in Clipboard
Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
O'Regan RM, Khuri FR.
O'Regan RM, et al.
Endocr Relat Cancer. 2004 Jun;11(2):191-205. doi: 10.1677/erc.0.0110191.
Endocr Relat Cancer. 2004.
PMID: 15163298
Review.
Item in Clipboard
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D.
André F, et al. Among authors: o regan r.
J Clin Oncol. 2016 Jun 20;34(18):2115-24. doi: 10.1200/JCO.2015.63.9161. Epub 2016 Apr 18.
J Clin Oncol. 2016.
PMID: 27091708
Clinical Trial.
Item in Clipboard
Chemoprevention of breast cancer.
O'Regan RM.
O'Regan RM.
Lancet. 2006 Apr 29;367(9520):1382-3. doi: 10.1016/S0140-6736(06)68594-2.
Lancet. 2006.
PMID: 16650636
No abstract available.
Item in Clipboard
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP.
Shulman LN, et al. Among authors: o regan r.
J Clin Oncol. 2014 Aug 1;32(22):2311-7. doi: 10.1200/JCO.2013.53.7142. Epub 2014 Jun 16.
J Clin Oncol. 2014.
PMID: 24934787
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite